|
| Cytogenetic classification | FLT3-ITD status | Mutations | Overall risk profile |
|
| Favorable | Negative | t(15;17) (q22;q12)
PML-RARA | Favorable |
| Favorable | Positive
(30–35% of cases) | t(15;17)(q22;q12)
PML-RARA | Usually favorable, but patients with long FLT3-ITD and low PML-RARA expression have less favorable prognosis and patients with high FLT3-ITD/FLT3-WT ratio |
| Intermediate or normal karyotype | Negative | DNMT3A mutation | Intermediate |
| Intermediate or normal karyotype | Positive (40% of cases) | DNMT3A mutation | Unfavorable |
| Intermediate or normal karyotype | Negative | NPM1 mutation | Favorable |
| Intermediate or normal karyotype | Positive (30–40% of cases) | NPM1 mutation | Intermediate (low FLT3-ITD/FLT3-WT ratio),
unfavorable (high FLT3-ITD/FLT3-WT ratio) |
| Intermediate or normal karyotype | Negative | No NPM1 mutation | Usually intermediate; unfavorable (some cases) |
| Intermediate or normal karyotype | Positive (15–20% of cases) | No NPM1 mutation | Intermediate; unfavorable
(associated with a stemness signature) |
| Intermediate or normal karyotype | Negative | CEBPA double mutant | Favorable |
| Intermediate or normal karyotype | Positive (6% of cases) | CEBPA double mutant | Intermediate |
| Intermediate or normal karyotype | Negative | CEBPA single mutant | Unfavorable |
| Intermediate or normal karyotype | Positive (30–40% of cases) | CEBPA single mutant | Unfavorable |
| Intermediate or normal karyotype | Negative | MLL PTD | Unfavorable |
| Intermediate or normal karyotype | Positive (30–35% of cases) | MLL PTD | Unfavorable |
| Unfavorable | Negative | Various mutations | Unfavorable |
| Unfavorable | Positive (6-7% of cases) | Various mutations | Unfavorable |
|
